Does the tablet form actually solve the adherence problem?
The main barrier an orally disintegrating tablet (ODT) addresses is adherence—taking the medication consistently. In CML, adherence is crucial because missing doses can lead to loss of response and disease progression. The 2025 JAMA review emphasizes that 'medication adherence is important to maintain treatment responsiveness' [1]. An ODT removes the need to swallow a pill with water, which can help patients who have difficulty swallowing or who find daily pill-taking burdensome. However, the evidence here doesn't directly measure ODTs; it underscores that adherence is a known challenge, and any formulation that makes taking the drug easier is a step in the right direction. But it's not a magic bullet—patients still need to remember to take it every day, and the underlying need for continuous therapy remains.
Even with TKIs, patients lose quality-adjusted life years—does the tablet change that?
TKIs have transformed CML from a fatal disease to a manageable chronic condition, but that doesn't mean patients get their full life back in terms of quality. A Swedish study of 991 chronic-phase CML patients found that while life expectancy loss was relatively small (9-15% compared to the general population), the loss in quality-adjusted life expectancy was much larger—29-33% [2]. This means patients live nearly as long, but with a significant burden of side effects and treatment-related impacts on well-being. An ODT doesn't address these quality-of-life losses; it only makes the act of taking the drug easier. So, while it might improve convenience, it doesn't solve the broader issue of treatment-related morbidity.
What about side effects—do ODTs reduce them?
No, the tablet form doesn't change the drug's side effects. The 2025 JAMA review lists specific adverse effects for each TKI: dasatinib can cause pleural effusion, nilotinib and ponatinib are linked to cardiovascular events, bosutinib causes gastrointestinal issues, and asciminib can increase pancreatic enzymes [1]. A separate 2025 review in JACC: CardioOncology highlights that cardiovascular disease is notably prevalent in CML patients and that TKIs like nilotinib and ponatinib are associated with vascular complications [5]. These risks are inherent to the drug, not the formulation. So, an ODT might make it easier to take the drug, but it doesn't make the drug safer. Patients still need careful monitoring and management of these side effects.
Can patients ever stop taking TKIs? Does the tablet help with that?
Some patients can stop TKIs if they achieve a deep molecular response, but this is not guaranteed. A pediatric study of 22 patients who discontinued TKIs after sustained deep response found that 50% remained in treatment-free remission at 12 months, while the other half lost major molecular response within 4 months and had to resume therapy [3]. Importantly, all who resumed regained their response, and no progression occurred. This suggests that for some, TKI therapy can be paused, but for many, it's lifelong. An ODT doesn't influence this—it's about the disease biology and treatment response, not the pill format. So, while ODTs might make long-term therapy more tolerable, they don't change the fundamental need for ongoing treatment in most patients.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2022 to 2025, 3 from 2024 or later, 2 in Q1 journals, collectively cited 76 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 57 papers retrieved from a database of over 500 million.
Sources used in this answer
Chronic Myeloid Leukemia
A 2025 JAMA review states that TKIs have reduced CML-related mortality from 10-20% per year to 1-2%, making survival similar to the general population, but emphasizes that adherence is critical and each TKI has specific side effects like cardiovascular risks and pleural effusion.
Loss in Overall and Quality‐Adjusted Life Expectancy for Patients With Chronic‐Phase Chronic Myeloid Leukemia
A Swedish register study of 991 chronic-phase CML patients found that while life expectancy loss was only 9-15%, quality-adjusted life expectancy loss was 29-33%, indicating a significant burden of treatment-related quality-of-life impairment.
Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia
A prospective pediatric study of 22 patients who discontinued TKIs after deep molecular response found a 50% treatment-free remission rate at 12 months; all who relapsed regained response upon resuming therapy, with no progression.
Correlation of Sokal Scoring System with Molecular Response in pts of CML Taking CML Specific Tyrosine Kinase Inhibitors
A descriptive case series of 260 CML patients in Pakistan found that after 3 months of TKI treatment, no patient achieved complete molecular response, though Sokal risk scores regressed, suggesting early response is limited.
Cardiovascular Disease in Patients With Chronic Myeloid Leukemia
A 2025 review in JACC: CardioOncology highlights that cardiovascular disease is prevalent in CML patients and that TKIs like dasatinib, nilotinib, and ponatinib are associated with cardiovascular side effects, underscoring the need for systematic documentation in trials.